George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

Core Insights - Longeveron Inc. has elected Dr. George Paletta, Jr. to its Board of Directors, bringing extensive experience in medicine and entrepreneurship to the company [2][3] - The company is focused on developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, with a promising pipeline of stem cell therapies [2][6] Company Overview - Longeveron is a clinical stage biotechnology company that develops regenerative medicines to address unmet medical needs, with its lead product being laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy [6] - The company is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, Pediatric Dilated Cardiomyopathy (DCM), and Aging-related Frailty [6] - Laromestrocel has received five important FDA designations, including Orphan Drug designation and Fast Track designation for the HLHS program [6] Leadership and Expertise - Dr. Paletta is a recognized orthopedic surgeon and has significant experience in developing ambulatory surgical centers, having participated in the sale of two ASCs valued at nearly $1 billion [2][3] - He holds multiple patents in orthopedic and cardiovascular fields and has been involved in various start-up ventures, providing advisory roles [3][4] - Dr. Paletta's educational background includes a Doctor of Medicine from Johns Hopkins University and an MBA from Washington University in St. Louis [4]